Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tamoxifen reduces the risk of benign breast disease

19.02.2003


Tamoxifen appears to reduce the risk of benign breast disease and may result in fewer biopsies, according to an analysis of data from a major randomized clinical trial of tamoxifen. The findings appear in the February 19 issue of the Journal of the National Cancer Institute.



Tamoxifen was shown in the Breast Cancer Prevention Trial to reduce the incidence of invasive and noninvasive breast cancer by as much as 50% compared to placebo. Other studies have suggested that tamoxifen can also decrease the size of benign breast lesions, which have been associated with a modest increase in the risk for developing invasive breast cancer.

To examine the effect of tamoxifen on the risk of developing benign breast lesions, Elizabeth Tan-Chiu, M.D., of the Cancer Research Network in Plantation, Fla., and her coworkers from the National Surgical Adjuvant Breast and Bowel Project examined the incidence of benign breast disease among 13,203 women treated with either tamoxifen or a placebo as part of the Breast Cancer Prevention Trial. The authors also noted how many biopsies each group of women underwent.


Overall, tamoxifen treatment reduced the risk of benign breast disease by 28%. Women in the tamoxifen group were less likely to develop several types of benign diseases--adenosis, cysts, duct ectasia, fibrocystic disease, hyperplasia, and metaplasia--than women in the placebo group. Tamoxifen therapy also reduced the risk of fibroadenoma and fibrosis--two conditions that often result in biopsies. In fact, women in the tamoxifen group underwent 29% fewer biopsies than women in the placebo group. The authors note that the reduction in risk was mostly seen in women younger than age 50.

The authors conclude that, in the Breast Cancer Prevention Trial, "tamoxifen not only reduced the risk of invasive and noninvasive breast cancer but also reduced the risk of benign breast disease and the morbidity and costs of repeated diagnosis and treatment that are associated with it."

They point out, however, that tamoxifen treatment carries risks, such as stroke and endometrial cancer, and they add that they do not advocate the indiscriminate use of tamoxifen for the treatment of benign breast disease.



Contact: Lori Garvey, National Surgical Adjuvant Breast and Bowel Project, 412-330-4621; fax: 412-330-4645, lori.garvey@nsabp.org

Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95:302–7.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Linda Wang | EurekAlert!
Further information:
http://jncicancerspectrum.oupjournals.org/

More articles from Health and Medicine:

nachricht 'Icebreaker' protein opens genome for t cell development, Penn researchers find
21.02.2018 | University of Pennsylvania School of Medicine

nachricht Similarities found in cancer initiation in kidney, liver, stomach, pancreas
21.02.2018 | Washington University School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Researchers invent tiny, light-powered wires to modulate brain's electrical signals

21.02.2018 | Life Sciences

The “Holy Grail” of peptide chemistry: Making peptide active agents available orally

21.02.2018 | Life Sciences

Atomic structure of ultrasound material not what anyone expected

21.02.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>